The next booster could be Israeli

The CEO of NRx – the US company in charge of trials of Israel’s BriLife coronavirus vaccine – said NRx is designing a Phase II study of BriLife as a booster to protect against COVID-19 variants. The study will be led by the research heads of Israel’s Hadassah and Sourasky (Ichilov) hospitals.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published.